8-K: Tharimmune, Inc. Reports 11.7 Million Shares Outstanding
Current Report
Tharimmune, Inc. disclosed that it has 11,739,676 shares of common stock issued and outstanding as of February 8, 2024.
Summary
- Tharimmune, Inc. filed a Form 8-K report on February 8, 2024.
- The report states that as of February 8, 2024, the company has 11,739,676 shares of common stock issued and outstanding.
Sentiment
Score: 5
Explanation: The document is a neutral disclosure of share information, neither positive nor negative.
Industry Context
This is a standard disclosure for publicly traded companies to inform investors of the current share structure.
Comparison to Industry Standards
- The disclosure of shares outstanding is a routine practice for all publicly listed companies, including those in the biotechnology sector like Tharimmune.
- Companies such as BioNTech and Moderna also regularly report their share counts in their filings.
- This information is crucial for investors to calculate market capitalization and per-share metrics.
Stakeholder Impact
- This information is relevant to shareholders as it provides an update on the total number of shares outstanding, which is important for calculating ownership percentages and per-share values.
Key Dates
| Date | Description |
|---|---|
| February 8, 2024 | Date of the report and the date for the number of shares outstanding. |
Keywords
shares outstanding, common stock, Form 8-K, Tharimmune
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.